US 12,319,745 B2
Antibodies having specificity for CD38 and uses thereof
Armand Bensussan, Paris (FR); Jean-Christophe Bories, Paris (FR); Maxime Fayon, Paris (FR); and Carolina Martinez-Cingolani, Paris (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); and UNIVERSITE DE PARIS, Paris (FR)
Appl. No. 17/627,674
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITÉ DE PARIS, Paris (FR)
PCT Filed Jul. 15, 2020, PCT No. PCT/EP2020/070057
§ 371(c)(1), (2) Date Jan. 16, 2022,
PCT Pub. No. WO2021/009263, PCT Pub. Date Jan. 21, 2021.
Claims priority of application No. 19186591 (EP), filed on Jul. 16, 2019.
Prior Publication US 2022/0251234 A1, Aug. 11, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/33 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2896 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/33 (2025.01); A61K 40/4222 (2025.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01)] 25 Claims
 
1. A monoclonal antibody having binding specificity for the extracellular domain of CD38 which comprises:
a heavy chain comprising i) the H-CDR1 as set forth in SEQ ID NO:5, ii) the H-CDR2 as set forth in SEQ ID NO:6 and iii) the H-CDR3 as set forth in SEQ ID NO:7, and,
a light chain comprising i) the L-CDR1 as set forth in SEQ ID NO:8, ii) the L-CDR2 as set forth in SEQ ID NO:9 and iii) the L-CDR3 as set forth in SEQ ID NO:10.